EUVIMEDEUVIMED entdecken
Crossref

DNA-engineered immunosensing platform for ultrasensitive detection of clinical protein biomarkers

Wenhao Zhang, Wenzhi Yang, Junru Li, Peipei Zhao, Weiqiang Yang, Shan Cao, Yongming Han, Xiaohan Cai, Siqi Tian, Jinxinyi Xu, Huili Dai, Dayong Yang und 2 weitere

Biosensors and Bioelectronics · 2026-05 · 300 · 118485

DOI: 10.1016/j.bios.2026.118485 ↗

Kurz gefasst

Fachartikel in der Zeitschrift Biosensors and Bioelectronics, 2026-05. Verfasst von Wenhao Zhang und 13 weiteren Autor:innen. Beteiligte Einrichtung: State Key Laboratory of Systems Medicine for Cancer, Shanghai Cancer Institute, Renji Hospital, School of Medicine, Shanghai Jiao Tong University, Sh…. Hauptthemen laut MEDLINE: Biosensing Techniques, Lipocalin-2, Troponin I, Interleukin-6. Die Arbeit wurde bisher 2-mal zitiert (Crossref) und nennt 44 Literaturangaben. Gefördert von: Shanghai Municipal Natural Science Foundation, Shanghai Jiao Tong University, National Natural Science Foundation of China.

AbstractSchlagwörterBibliografische AngabenZitierenVerwandte Studien

Abstract (Originalsprache)

Detection of protein biomarkers is crucial for early diagnosis, dynamic monitoring, and prognosis evaluation of various diseases. However, the surface immobilization methods of capture probes directly affect the detection performance of immunosensors. Herein, a DNA-engineered immunosensing platform (DEISP) for ultrasensitive detection of clinical protein biomarkers is presented, which employs DNA duplexes to immobilize capture antibodies on the sensing interface. This DNA-engineered immobilization approach not only firmly anchors the capture antibody with excellent biocompatibility, but also preserves its binding sites for target molecules. As proof of concept, DEISP was employed to detect the kidney injury biomarker neutrophil gelatinase-associated lipocalin (NGAL), the pro-inflammatory cytokine interleukin-6 (IL-6), and the cardiac troponin I (cTnI) associated with myocardial infarction, demonstrating remarkable sensitivity with limits of detection (LODs) of 0.025 pg mL-1 for NGAL, 0.026 pg mL-1 for IL-6, and 2.35 pg mL-1 for cTnI, as well as a dynamic range spanning 7 orders of magnitude. Moreover, DEISP exhibits 91% accuracy in clinical serum and urine samples and a total assay time of 90 min. Furthermore, DEISP significantly minimizes sample volume and simplifies operational procedures while achieving ultrahigh sensitivity, highlighting its potential for point-of-care testing (POCT), multi-marker screening, and precision medicine.

Schlagwörter

MeSH-Schlagwörter (MEDLINE)

Biosensing TechniquesLipocalin-2Troponin IInterleukin-6DNAHumansBiomarkersImmunoassayLimit of DetectionAntibodies, ImmobilizedMyocardial Infarction

Stichwörter der Autor:innen

DNAImmunosensingLiquid biopsyProtein detectionUniversal

Substanzen

Lipocalin-2BiomarkersTroponin IInterleukin-6Antibodies, ImmobilizedLCN2 protein, humanDNA

Autor:innen und Institutionen

  • State Key Laboratory of Systems Medicine for Cancer, Shanghai Cancer Institute, Renji Hospital, School of Medicine, Shanghai Jiao Tong University, Shanghai, 200032, PR China; Shanghai Key Laboratory of Cancer System Reg…
  • Emergency Department, Renji Hospital, School of Medicine, Shanghai Jiao Tong University, Shanghai, 200127, PR China.
  • Department of Chemistry, State Key Laboratory of Molecular Engineering of Polymers, Shanghai Key Laboratory of Molecular Catalysis and Innovative Materials, College of Chemistry and Materials, Fudan University, Shanghai…

Förderung

  • Shanghai Municipal Natural Science Foundation
  • Shanghai Jiao Tong University
  • National Natural Science Foundation of China
  • Innovative Research Team of High-level Local University in Shanghai
  • Shanghai Municipal Health Commission

Zitieren

APA

Zhang, W., Yang, W., Li, J., Zhao, P., Yang, W., Cao, S., Han, Y., Cai, X., Tian, S., Xu, J., Dai, H., Yang, D., Li, F., & Liu, P. (2026). DNA-engineered immunosensing platform for ultrasensitive detection of clinical protein biomarkers. Biosensors and Bioelectronics, 300, 118485. https://doi.org/10.1016/j.bios.2026.118485

Vancouver

Zhang W, Yang W, Li J, Zhao P, Yang W, Cao S, et al. DNA-engineered immunosensing platform for ultrasensitive detection of clinical protein biomarkers. Biosensors and Bioelectronics. 2026;300:118485. doi:10.1016/j.bios.2026.118485

BibTeX
@article{Zhang2026,
  author = {Zhang, Wenhao and Yang, Wenzhi and Li, Junru and Zhao, Peipei and Yang, Weiqiang and Cao, Shan and Han, Yongming and Cai, Xiaohan and Tian, Siqi and Xu, Jinxinyi and Dai, Huili and Yang, Dayong and Li, Fengqin and Liu, Peifeng},
  title = {DNA-engineered immunosensing platform for ultrasensitive detection of clinical protein biomarkers},
  journal = {Biosensors and Bioelectronics},
  year = {2026},
  volume = {300},
  pages = {118485},
  doi = {10.1016/j.bios.2026.118485}
}
Kostenlos starten →